Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
930
datasets available to search
ShareScore release 0.9.0
Dataset results
930 results for “induced pluripotent stem cells”
Characterization of a loss-offunction NSF attachment protein beta mutation in monozygotic triplets affected with epilepsy and autism using cortical neurons from proband-derived and CRISPR-corrected induced pluripotent stem cell lines
<p>RNA-seq data of matured cortical neurons (8-weeks old) derived from the induced pluripoent stem cells (iPSC) of control parents (CtrlF and CtrlM) and corrected proband. There are three replicates (Rep1, Rep2, Rep3) for each sample with Forwad read (R1_001.fastq.gz)</p> <p>CtrlF: Control Father sample</p> <p>CtrlM: Control mother sample</p> <p>NDD_01_Corr_Het: Heterozygous correction of NAPB mutation (c.354+2T>G) in NDD_01 proband</p> <p>NDD_05_Corr_Hom: Homozygous correction of NAPB mutation (c.354+2T>G) in NDD_05 proband</p>
Efficient embryoid-based method to improve generation of optic vesicles from human induced pluripotent stem cells data
<p>Animal models have provided many insights into ocular development and disease, but they remain suboptimal for understanding human oculogenesis. Eye development requires spatiotemporal gene expression patterns and disease phenotypes can differ significantly between humans and animal models, with patient-associated mutations causing embryonic lethality reported in some animal models. The emergence of human induced pluripotent stem cell (hiPSC) technology has provided a new resource for dissecting the complex nature of early eye morphogenesis through the generation of three-dimensional (3D) cellular models. By using patient-specific hiPSCs to generate <em>in vitro </em>optic vesicle-like models, we can enhance the understanding of early developmental eye disorders and provide a pre-clinical platform for disease modelling and therapeutics testing. A major challenge of <em>in vitro </em>optic vesicle generation is the low efficiency of differentiation in 3D cultures. To address this, we adapted a previously published protocol of retinal organoid differentiation to improve embryoid body formation using a microwell plate. Established morphology, upregulated transcript levels of known early eye-field transcription factors and protein expression of standard retinal progenitor markers confirmed the optic vesicle/presumptive optic cup identity of <em>in vitro </em>models between day 20 and 50 of culture. This adapted protocol is relevant to researchers seeking a physiologically relevant model of early human ocular development and disease with a view to replacing animal models.</p>
Generation of beta-like cell subtypes from differentiated human induced pluripotent stem cells in 3D spheroids
<p>This repository contains single-cell RNA-sequencing data files (raw FASTQ files generated from Illumina HiSeq sequencing) related to the article entitled "Generation of beta-like cell subtypes from differentiated human induced pluripotent stem cells in 3D spheroids" by Lisa Morisseau et al. (2023) published in the Molecular Omics journal (DOI: 10.1039/d3mo00050h).</p> <p> </p>
GC-MS raw data_Figure 6E_Lysophosphatidic Acid Shifts Metabolic and Transcriptional Landscapes to Induce a Distinct Cellular State in Human Pluripotent Stem Cells
<p><strong>Sample name</strong></p> <p>hESCs (H1 cells) were given treatments for two days and then collected for GC-MS analysis.</p> <p>E8: E8 medium</p> <p>AX: E8 + 1.6% AlbuMAX;</p> <p>BSA: E8 + 1% albumin;</p> <p>BSA+hCDL: E8 + 1% albumin + 0.1% hCDL;</p> <p>LPA+BSA: E8 + 1 μM LPA + 1% albumin;</p> <p>LPA+BSA+hCDL: E8 + 1 μM LPA + 1% albumin + 0.1% hCDL</p> <p>STD: standard lipids mixture used as reference</p> <p><strong>Extraction and Methylation</strong></p> <p>Sample preparation was conducted according to the previously reported method (Araujo et al., 2008) with the modification. Briefly, spent medium was removed, and cells were rinsed with 1 mL/well 0.9% (w/v) saline twice. Then 0.5 mL/well -80°C 80% methanol was added to quench the metabolism. Five wells of cells (from 6-well plate) were scrapped off into a glass screw-cap tube. Then 4 mL heptadecanoate containing chloroform (4 μg/mL, internal standard for fatty acids) was added into the tube. Vortex, and then centrifuge at 2000 rpm for 5 min. Cellular debris was carefully removed, and nitrogen blow the solution till dry. Add 1.5 mL hexane and 1.5 mL 14% boron trifluoride (BF<sub>3</sub>)/methanol solution. Seal the tube with nitrogen gas, heat it at 100°C for 1 h using MK200-2 dry bath incubator (Aosheng), and then cool down to room temperature. Add 1 mL water into the tube, vortex and then centrifuge at 3000 rpm for 10 min. The upper layer was transferred into a new 1.5-mL eppendorf tube and evaporated by nitrogen gas. The residue was re-dissolved in 100 μL hexane for GC-MS analysis.</p> <p><strong>GC-MS method</strong></p> <p>Samples were analyzed using an Agilent GC-MS system (Agilent) consisting of a 6890 gas chromatography and a 5973 mass spectrometer. Fatty acid methyl esters were separated by an Omegawax™ 250 fused silica capillary column (30 m × 0.25 mm i.d., 0.25 μm film thickness, Supelco, Bellefonte, PA). The optimized oven temperature program was: initial temperature set at 180°C and held for 3 min; ramped to 206°C at 2°C/min and held at 206°C for 25 min, then, ramped to 240°C at 10°C/min and held for 5 min. Overall, the total run time was 50 min. Carrier gas was high-purity helium at a flow rate of 1.5 mL/min. Injector temperature was set at 250°C. Injection volume was 2 μL with a split ratio of 1:15. The mass spectrometer was operated in electron-impact (EI) mode at 70 eV ionization energy. The temperatures of quadrupole and ionization source were set at 150°C and 280°C, respectively. The spectra from 3 to 50 min were acquired with the <em>m/z</em> range of 35–550 at a scan rate of 0.34 s per scan.</p>
LC-MS raw data_Lysophosphatidic Acid Shifts Metabolic and Transcriptional Landscapes to Induce a Distinct Cellular State in Human Pluripotent Stem Cells
<p><strong>LC-MS/MS analysis</strong></p> <p><strong>Metabolite extraction</strong></p> <p>For LC-MS/MS quantification, cell sample preparation was conducted as described in the previous literatures (Ying, Kimmelman et al. 2012, Zhang, Badur et al. 2016). Briefly, the spent medium was removed, and cells were rinsed with 1 mL/well 0.9% (w/v) saline twice. Then 0.5 mL/well -80°C 0.2 μg/mL norvaline containing 80% methanol was added to quench the metabolism. Cells were scraped off into 1.5-mL eppendorf tube and stored in -80℃ overnight. The mixtures were vortexed and then centrifuged 12500 × <em>g </em>for 15 min at 4℃. The supernatant was used for LC-MS analysis.</p> <p><strong>LC-MS/MS method</strong></p> <p>Waters Xevo TQD coupled with Waters Acquity UPLC system was used for quantification. Acquity UPLC BEH HILIC column (2.1 × 100 mm, 1.7 μm), Acquity UPLC BEH C18 column (2.1 × 100 mm, 1.7 μm), and Acquity UPLC BEH amide column (2.1 × 100 mm, 1.7 μm) were used for the separation of metabolites. Column temperature was set at 40 °C.</p> <p>For the quantification of norvaline, amino acids, GSH, GSSG, SAH, SAM, ascorbic acid and myo-inositol, amide column was used for the separation. Acetonitrile with 0.1% formic acid (A) and water with 0.1% formic acid (B) were used as mobile phases. The gradient setting is: 0-4 min, 99% A to 90% A; 4-10 min, 90% A to 67% A; 10-13 min, 67% A to 1% A; 13-15 min, 1% A; 15-16.5 min, 1% A to 99% A; 16.5-20 min, 99% A. Flowrate was set as 0.4 mL/min.</p> <p>For the quantification of metabolites involved in TCA cycle, energy related and ribonucleotides, an amide column was used for the separation. Acetonitrile with 0.1% formic acid (A) and water with 0.1% formic acid (B) were used as mobile phases. The gradient setting is: 0-2 min, 80% A; 2-3 min, 80% A to 20% A; 3-5 min, 20% A; 5-6 min, 20% A to 80% A; 6-10 min, 80% A. Flowrate was set as 0.4 mL/min.</p> <p>For the quantification of acetate, acetyl-CoA and metabolites involved in glycolysis and pentose phosphate pathway, HILIC column was used for the separation. Acetonitrile (A) and 10 mM ammonium bicarbonate were used as mobile phases. The gradient setting is: 0-2 min, 10% A; 2-5 min, 10% A to 5% A; 5-6 min, 5% A to 10% A; 6-10 min, 10% A. Flowrate was set as 0.2 mL/min.</p> <p>For the quantification of LPA, LPC and PC, HILIC column was used for the separation. Acetonitrile (A) and 10 mM ammonium bicarbonate aqueous solution (B) were used as mobile phases. The gradient setting is: 0-2 min, 95% A; 2-4 min, 95% A to 10% A; 4-7 min, 10% A; 7-9 min, 10% A to 95% A; 9-15 min, 95% A. Flowrate was set as 0.2 mL/min.</p> <p>For the quantification of CDL lipids, C18 column was used for the separation. 98% Acetonitrile aqueous solution (A) and 10 mM ammonium acetate 90% acetonitrile aqueous solution (B) were used as mobile phases. The gradient setting is: 0-5 min, 0.1% A; 5-6 min, 0.1% A to 99.9% A; 6-11 min, 99.9% A; 11-12 min, 99.9% A to 0.1% A; 12-15 min, 0.1% A. Flowrate was set as 0.4 mL/min.</p> <p>Argon was used as source gas, capillary voltage was 3500 V, and desolvation temperature was 500 °C. Multiple reaction monitoring (MRM) was conducted, and the ion transitions are listed in the supplemental Table S2. Selected ion recording (SIR) was conducted for the detection of CDL-related lipids, and the setting is listed in the supplemental Table S3.</p> <p>Standard solutions of TCA metabolites (100 μg/mL) and intermediates of glycolysis and pentose phosphate pathway (10 μg/mL) were prepared to confirm the retention time. Peak intensity of product ion was used for the quantification. Data analysis was performed by TargetLynx software (Waters) with statistical analysis in Graphpad Prism (version 8.4.0) and R.</p>
Gene expression counts from induced Pluripotent Stem Cells
<p><strong>File description:</strong></p> <ol> <li> <p>Gene-level counts using the gtf file from the release 34 of GENCODE <a href="https://www.gencodegenes.org/human/release_34">https://www.gencodegenes.org/human/release_34</a></p> </li> <li> <p>Split counts spanning from one exon to another using an annotation-free algorithm, therefore capturing new splice sites</p> </li> <li> <p>Non-split counts covering exon-intron boundaries</p> </li> <li> <p>Sample annotation describing each sample from the dataset</p> </li> <li> <p>Description file with global information from the dataset</p> </li> </ol> <p><strong>Use: </strong>The count matrices are intended to help researchers that are interested in using RNA-Seq data with the purpose of diagnostics. Researchers can merge their own dataset with the downloaded ones, provided the tissue, genome build, strand, and paired-end specifications match. Afterwards, the workflow DROP can be used to compute expression and splicing outliers (<a href="https://github.com/gagneurlab/drop">https://github.com/gagneurlab/drop</a>).</p> <p><strong>Maintainer: </strong>Vicente A. Yépez, <a href="mailto:yepez@in.tum.de">yepez@in.tum.de</a></p> <p><strong>URL:</strong> <a href="https://github.com/gagneurlab/drop/">https://github.com/gagneurlab/drop/</a></p> <p> </p> <p><strong>Title: </strong>induced Pluripotent Stem Cells<br> <strong>Number of samples:</strong> 330<br> <strong>Tissue:</strong> iPSCs<br> <strong>Organism:</strong> Homo sapiens<br> <strong>Genome assembly:</strong> hg19<br> <strong>Gene annotation:</strong> gencode34<br> <strong>Disease:</strong> None<br> <strong>Strand specific:</strong> True<br> <strong>Paired end:</strong> True<br> <strong>Dataset contact:</strong> Marc Bonder, marcj89 at gmail.com</p> <p><strong>Citation:</strong> Cite both the resource using Zenodo's citation and the publication under References</p>
Patient-specific induced pluripotent stem cell properties implicate Ca2+-homeostasis in clinical arrhythmia associated with combined heterozygous RYR2 and SCN10A variants
<p class="MsoNormal"><span>We illustrate the use of induced pluripotent stem cells (iPSCs) as platforms for investigating cardiomyocyte phenotypes in a human family pedigree exemplified by novel heterozygous RYR2-A1855D and SCN10A-Q1362H variants occurring alone and in combination. The proband, a four-month-old boy, presented with </span><span>polymorphic</span><span> ventricular tachycardia (</span><span>P</span><span>VT). Genetic tests revealed double novel heterozygous RYR2-A1855D and SCN10A-Q1362H variants inherited from his father (F) and mother (M) respectively. His father showed ventricular premature beats (VPB); his mother was asymptomatic. Molecular biological characterisations demonstrated greater <em>TNNT2</em> mRNA expression in the iPSCs-induced cardiomyocytes (iPS-CMs) than in the iPSCs</span><span>.</span><span> </span><span>c</span><span>TNTs became progressively organised, but cytoplasmic RYR2 and SCN10A aggregations occurred in the iPS-CMs. Proband-specific iPS-CMs showed decreased <em>RYR2</em> and <em>SCN10A</em> mRNA expression. The RYR2-A1855D variant resulted in premature spontaneous sarcoplasmic reticular (SR) Ca<sup>2+</sup> transients (PCTs), Ca<sup>2+</sup> oscillations (COs), and increased action potential durations (APDs). SCN10A-Q1362H did not confer any specific phenotype. However, the </span><span>combined </span><span>heterozygous RYR2-A1855D and SCN10A-Q1362H variants in the proband iPS-CMs resulted in accentuated Ca<sup>2+</sup> homeostasis disorders, AP prolongation and susceptibility to early afterdepolarisations (EADs) at high stimulus frequencies. These findings attribute the clinical phenotype in the proband to effects of the heterozygous <em>RYR2</em> variant exacerbated by heterozygous <em>SCN10A</em> modification. </span></p>
Patient-specific induced pluripotent stem cell properties implicate Ca2+-homeostasis in clinical arrhythmia associated with combined heterozygous RYR2 and SCN10A variants
Open the record for dataset details and reuse information.
Induced pluripotent stem cell-derived cardiomyocyte in vitro models: tissue fabrication protocols, assessment methods, and quantitative maturation metrics for benchmarking progress
<p>The advent of human induced pluripotent stem cells (hiPSCs) and techniques to differentiate cardiomyocytes from them has opened a viable path to creating <em>in vitro</em> models of normal and diseased hearts, accelerating more predictive drug screening and therapeutic strategies for cardiac pathologies. Currently, hiPSC-derived cardiomyocytes (hiPSC-CMs) are more similar to fetal than adult cardiomyocytes, leading many in the field to explore approaches to enhance cell and tissue maturation. There are over 2,000 studies utilizing hiPSC-CMs in models composed of various combinations of cell and extracellular matrix components, using a plethora of differentiation protocols, culture formats, and methods for quantifying cardiomyocyte function. To assess the current state of this rapidly growing area, we systematically analyzed 300 studies using hiPSC-CM models for their selection of hiPSC lines, hiPSC-CM differentiation protocols, types of <em>in vitro </em>models, maturation techniques, and metrics used to assess cardiomyocyte functionality and maturity. Here, we provide the data compiled from our analysis of these papers so others in the field can utilize it to inform their research.</p> <p>Based on this analysis, we highlight the diversity of, and current trends in, <em>in vitro</em> model designs and highlight the most common and promising practices for functional assessments. We further analyzed outputs spanning structural maturity, contractile function, electrophysiology, and gene expression and note field-wide improvements over time. Finally, we observe that a persistent lack of coordination amongst investigators is limiting the field's ability to benchmark and advance hiPSC-CM function against previous studies. We discuss opportunities to collectively pursue the common goal of hiPSC-CM model development, maturation, and assessment that we believe are critical to drive the entire community forward in engineering mature cardiac tissue.</p>
Transcriptomic characterization of 2D and 3D human induced pluripotent stem cell-based in vitro models as New Approach Methodologies for developmental neurotoxicity testing
<p><strong>Abstract:</strong> The safety and developmental neurotoxicity (DNT) potential of chemicals remain critically understudied due to limitations of current in vivo testing guidelines, which are low throughput, resource-intensive, and hindered by species differences that limit their relevance to human health. To address these issues, robust new approach methodologies (NAMs) using deeply characterized cell models are essential. This study presents the comprehensive transcriptomic characterization of two advanced human-induced pluripotent stem cell (hiPSC)-derived models: a 2D adherent and a 3D neurosphere model of human neural progenitor cells (hiNPCs) differentiated up to 21 days. Using high-throughput RNA sequencing, we compared gene expression profiles of 2D and 3D models at three developmental stages (3, 14, and 21 days of differentiation). Both models exhibit maturation towards post-mitotic neurons, with the 3D model maturing faster and showing a higher prevalence of GABAergic neurons, while the 2D model is enriched with glutamatergic neurons. Both models demonstrate broad applicability domains, including excitatory and inhibitory neurons, astrocytes, and key endocrine and especially the understudied cholinergic receptors. Comparison with human fetal brain samples confirms their physiological relevance. This study provides novel in-depth applicability insights into the temporal and dimensional aspects of hiPSC-derived neural models for DNT testing. The complementary use of these two models is highlighted: the 2D model excels in synaptogenesis assessment, while the 3D model is particularly suited for neural network formation as observed as well in previous functional studies with these models. This research marks a significant advancement in developing human-relevant, high-throughput DNT assays for regulatory purposes.</p> <p><strong>This data sets contains:</strong></p> <p><strong>Tab. S1</strong> - Significant genes results</p> <p><strong>Tab. S2</strong> - Enriched pathways_GO_Biological Processes</p> <p><strong>Tab. S3</strong> - Enriched pathways_GO_Cellular Components</p> <p><strong>Tab. S4</strong> - Enriched pathways_GO_Molecular Function</p> <p><strong>Tab. S5</strong> - Enriched pathways_KEGG</p> <p><strong>Tab. S6</strong> - EnrichEnriched pathways_Panther</p> <p><strong>Tab. S7</strong> - Enriched pathways_Reactome</p> <p><strong>Tab. S8</strong> - Gene counts</p> <p><strong>Tab. S9</strong> - Gene selection for targeted analysis</p>
Induced pluripotent stem cell-derived cardiomyocyte in vitro models: tissue fabrication protocols, assessment methods, and quantitative maturation metrics for benchmarking progress
Open the record for dataset details and reuse information.
Data from: A proteomics approach for the identification of cullin-9 (CUL9) related signaling pathways in induced pluripotent stem cell models
<p>CUL9 is a non-canonical and poorly characterized member of the largest family of E3 ubiquitin ligases known as the Cullin RING ligases (CRLs). Most CRLs play a critical role in developmental processes, however, the role of CUL9 in neuronal development remains elusive. We determined that deletion or depletion of CUL9 protein causes aberrant formation of neural rosettes, an in vitro model of early neuralization. In this study, we applied mass spectrometric approaches in human pluripotent stem cells (hPSCs) and neural progenitor cells (hNPCs) to identify CUL9 related signaling pathways that may contribute to this phenotype. Through LC-MS/MS analysis of immunoprecipitated endogenous CUL9, we identified several subunits of the APC/C, a major cell cycle regulator, as potential CUL9 interacting proteins. Knockdown of the APC/C adapter protein FZR1 resulted in a significant increase in CUL9 protein levels, however, CUL9 does not appear to affect protein abundance of APC/C subunits and adapters or alter cell cycle progression. Quantitative proteomic analysis of CUL9 KO hPSCs and hNPCs identified protein networks related to metabolic, ubiquitin degradation, and transcriptional regulation pathways that are disrupted by CUL9 deletion in both hPSCs and hNPCs. The results of our study build on current evidence that CUL9 may have unique functions in different cell types potentially contributing to the difficulty of identifying CUL9 substrates.</p> <p><strong>Information on data/files</strong>:</p> <p><em>Please first unzip Figure_4_CUL9-IP-LCMSMS-data.zip and Figure_7_iTRAQ-data.zip, then follow the description below.</em></p> <p>CUL9 immunoprecipitation from whole lysates collected for hPSCs were analyzed using LC/MS-MS. IgG was used as a control to determine proteins specifically enriched in the CUL9 IP. This data correlates to Figure 4 of the associated manuscript.</p> <p>Initial CUL9 immunoprecipitation was performed by VG and analyzed by LC-MS/MS at UNC.</p> <p>Fig4-LCMSMS_IPCUL9_Replicate1_UNC</p> <p>Two more immunoprecipitations were performed by VG and analyzed by LC-MS/MS at Vanderbilt University MSRC Proteomics Core. The first run (replicate 1) was used to produce the STRING figure in the associated manuscript, as well as the volcano plot in Supplemental Figure 8.</p> <p>Two Scaffold files contain raw data and our analysis parameters:</p> <ul> <li>Fig4-LCMSMS_IPCUL9_Replicate2_Vanderbilt</li> <li>Fig4-LCMSMS_LCMSMS_IPCUL9_Replicate3_Vanderbilt</li> </ul> <p>Excel files exported from the above Scaffold files contain the raw data in excel format including spectral counts, peptide counts, protein probability, and detailed raw data as it pertains to each identified protein. See these data sets in the folders below:</p> <ul> <li>Fig4-LCMSMS_IPCUL9_Run2_Vanderbilt_CompleteDataSet</li> <li>Fig4-LCMSMS_IPCUL9_Run3_Vanderbilt_CompleteDataSet</li> </ul> <p>CUL9 KO clones were used to identify proteins increased or decreased compared to parental wild-type cell lines using iTRAQ. This data correlates to Figure 8 of the associated manuscript. Two iTRAQ experiments were performed to identify proteins altered in CUL9 KO iPSCs, neural stem cells (NSCs), and NPCs. Each set of experiments was duplicated – each in a different isogenic CUL9 KO clone (Clone 20 or Clone B)</p> <p><strong>iTRAQ labeling of experiment one is as follows:</strong></p> <ol> <li>Label 115: Parental WT NSCs</li> <li>Label 117: CUL9 KO Clone 20 or B NSCs</li> <li>Label 114: Parental WT NPCs</li> <li>Label 116: CUL9 KO Clone 20 or B NPCs</li> </ol> <p>Files containing raw and analyzed data of experiment one are labeled as follows:</p> <ul> <li>Fig7_Experiment1_Clone 002_compared-to-NSC-WT</li> <li>Fig7_Experiment1_Clone001-compared-to-NSC-WT</li> <li>Fig7_Experiment1_Clone001iPSC_compared-to-iPSCWT</li> <li>Fig7_Experiment1_Clone002_compared-to-iPSCWT</li> </ul> <p><strong>iTRAQ labeling of experiment two is as follows:</strong></p> <p>For Clone 20:</p> <ol> <li>Label 115: Parental WT NSCs</li> <li>Label 117: CUL9 KO Clone 20 or B NSCs</li> <li>Label 114: Parental WT iPSCs</li> <li>Label 116: CUL9 KO Clone 20 or B iPSCs</li> </ol> <p>Files containing raw and analyzed data of experiment two are labeled as follows:</p> <ul> <li>Fig7_Experiment2_Clone001NPC_Compared-to-NPC-WT</li> <li>Fig7_Experiment2_Clone001NPC_Compared-to-NSC-WT</li> <li>Fig7_Experiment2_Clone002NPC_Compared-to-NPC-WT</li> <li>Fig7_Experiment2_Clone002NPC_Compared-to-NSC-WT</li> </ul> <p>Please note that the first tab of each excel document contains the full raw data set before analysis. All other tabs contain analyzed data comparing the proteins identified in two cell lines. Analyzed tabs are labeled to indicate which cell lines are being compared. Please note that the CUL9 isogenic clones Clone 20=Clone#1 and Clone B=Clone#2 as referenced in the associated manuscript.</p> <p>Detailed information about the protocols used for collection and analysis of this data can be found in the supplemental information within the associated manuscript.</p>
A targeted metabolomics-based assay using human induced pluripotent stem cell-derived cardiomyocytes identifies structural and functional cardiotoxicity potential
<p>Implementing screening assays that identify functional and structural cardiotoxicity earlier in the drug development pipeline has the potential to improve safety and the cost and time required to bring new drugs to market. In this study, a metabolic biomarker-based assay was developed that predicts the cardiotoxicity potential of a drug based on changes in the metabolism and viability of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM). Assay development and testing was conducted in two phases: (1) biomarker identification and (2) targeted assay development. In the first phase, metabolomic data from hiPSC-CM spent media following exposure to 66 drugs was used to identify biomarkers that identified both functional and structural cardiotoxicants. Four metabolites that represent different metabolic pathways (arachidonic acid, lactic acid, 2'-deoxycytidine, and thymidine) were identified as indicators of cardiotoxicity. In phase two, a targeted, exposure-based biomarker assay was developed that measured these metabolites and hiPSC-CM viability across an eight-point concentration curve. Metabolite-specific predictive thresholds for identifying the cardiotoxicity potential of a drug were established and optimized for balanced accuracy or sensitivity. When predictive thresholds were optimized for balanced accuracy, the assay predicted the cardiotoxicity potential of 81 drugs with 86% balanced accuracy, 83% sensitivity, and 90% specificity. Alternatively, optimizing the thresholds for sensitivity yields a balanced accuracy of 85%, 90% sensitivity, and 79% specificity. This new hiPSC-CM-based assay provides a paradigm that can identify structural and functional cardiotoxic drugs that could be used in conjunction with other endpoints to provide a more comprehensive evaluation of a drug's cardiotoxicity potential.</p>
Ice recrystallization inhibitors enable efficient cryopreservation of induced pluripotent stem cells: A functional and transcriptomic analysis
<p><span>The successful use of human induced pluripotent stem cells (iPSCs) for research or clinical applications requires the development of robust, efficient, and reproducible cryopreservation protocols. After cryopreservation, the survival rate of iPSCs is suboptimal and cell line dependent. We assessed the use of ice recrystallization inhibitors (IRIs) for cryopreservation of human iPSCs<span>. A toxicity screening study was performed to assess specific small-molecule carbohydrate-based IRI and concentrations for further evaluation.</span> Then, a cryopreservation study compared the cryoprotective efficiency of 15 mM IRIs in 5 % or 10 % DMSO-containing solutions and with CryoStor® CS10. Three iPSC lines were cryopreserved as single-cell suspensions in the cryopreservation solutions and post-thaw characteristics, including pluripotency and differential gene expression, were assessed. </span><span>W</span><span>e demonstrate the fitness-for-purpose of 15 mM IRI in 5 % DMSO as an efficient cryoprotective solution for iPSCs in terms of post-thaw recovery, viability, pluripotency, and transcriptomic changes. Given that this dataset is the first report where mRNA sequencing has been used to identify expression changes resulting from iPSCs cryopreservation, it has the potential to be used for molecular mechanism analysis relating to cryopreservation. IRIs can reduce DMSO concentrations, thereby improving the utility, effectiveness, and efficiency of cryopreservation. </span></p>
Generation of human induced pluripotent stem cells-derived cortical neurons for high throughput imaging of neurite morphology and neuron maturation
<p>Figure 5: Whole cell patch clamping showed the differentiated neurons are functional.</p>
Generation of human induced pluripotent stem cells-derived cortical neurons for high throughput imaging of neurite morphology and neuron maturation
<p>Figure 3 - Neurite outgrowth dataset. Comparing neurite outgrowth at Day1 and 15 post-seeding cortical neural progenitors. </p>
Patient Specific Induced Pluripotency Stem Cells (PSiPS)
ClinicalTrials.gov study NCT00953693. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells
ClinicalTrials.gov study NCT00801372. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure
ClinicalTrials.gov study NCT04396899. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy
ClinicalTrials.gov study NCT03407040. IPD Sharing: Not stated. Countries: 1. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.